OA - 64: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
OA – 50: Phase II study of iberdomide maintenance therapy post-autologous stem cell transplant in multiple myeloma: results of a planned interim analysis
OA – 53: Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – 4-Year-Follow-Up from the GMMG-CONCEPT trial
Location: 101 A1-A2, Convention Center
Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA
Oral Abstract Session
Wednesday, Sep 25th
12:18 PM – 12:30 PM East Coast USA Time
OA – 56: Single cell analyses of bone marrow immune microenvironment in RRMM subjects treated with MEK1/2 inhibitors reveal IRF1-mediated IFN/PDL1 signaling axes
OA – 46: Phase II clinical trial of minimal residual disease response-adapted deferral of transplantation in dysproteinemia (MILESTONE)
Location: 101 A1-A2, Convention Center
Speaker: Susan Bal, MD – University of Alabama at Birmingham
Oral Abstract Session
Thursday, Sep 26th
5:42 PM – 5:54 PM East Coast USA Time
OA – 49: Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)
OA – 52: Isatuximab plus lenalidomide and dexamethasone with bortezomib versus isatuximab plus lenalidomide and dexamethasone in newly diagnosed transplant ineligible Multiple Myeloma: The BENEFIT study.
OA – 55: Iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
OA – 01: Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM‑2 Study
Location: Plenary Hall, Pavilion 3
Speaker: Nizar J. Bahlis, MD – Arnie Charbonneau Cancer Institute - University of Calgary
Oral Abstract Session
Friday, Sep 27th
9:00 AM – 9:12 AM East Coast USA Time
OA – 19: Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 03: Talquetamab (tal) + Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up
Location: Plenary Hall, Pavilion 3
Speaker: Yael C. Cohen, MD (she/her/hers) – Tel- Aviv Sourasky (Ichilov) Medical Center, and Faculty of health Science, Tel Aviv University, Tel Aviv, Israel
Oral Abstract Session
Friday, Sep 27th
9:12 AM – 9:24 AM East Coast USA Time
OA – 20: A new circulating tumor cell-based prognostic system to refine patient stratification status of newly diagnosed Multiple Myeloma patients
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 08: Safety and preliminary efficacy of BMS-986393, a GPRC5D CAR T cell therapy, in patients (pts) with relapsed/refractory (RR) multiple myeloma (MM) and 1–3 prior regimens: results from a phase 1 study
Location: Plenary Hall, Pavilion 3
Speaker: Myo Htut, MD – City of Hope Comprehensive Cancer Center
Oral Abstract Session
Friday, Sep 27th
9:24 AM – 9:36 AM East Coast USA Time
OA – 21: Clinical implications of residual immunophenotypically normal plasma cells within bone marrow at various disease stages in multiple myeloma
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
Speaker: Wenqiang Yan, MD – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Oral Abstract Session
Friday, Sep 27th
9:36 AM – 9:48 AM East Coast USA Time
OA – 23: Differential Immunophenotypic and Genetic Landscapes of High-Risk and Standard-Risk Multiple Myeloma Patients
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 34: HBI0101, an anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
Location: Plenary Hall, Pavilion 3
Speaker: Yael C. Cohen, MD (she/her/hers) – Tel- Aviv Sourasky (Ichilov) Medical Center, and Faculty of health Science, Tel Aviv University, Tel Aviv, Israel
Oral Abstract Session
Friday, Sep 27th
9:48 AM – 10:00 AM East Coast USA Time
OA – 40: SWIFT-seq: Single-cell RNA sequencing of circulating tumor cells as a comprehensive clinically applicable liquid biopsy test for patients with multiple myeloma and its precursor conditions
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 60: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
Location: Plenary Hall, Pavilion 3
Speaker: Marc S. Raab, MD PhD (he/him/his) – Dept. of Medicine V Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Oral Abstract Session
Friday, Sep 27th
10:00 AM – 11:00 AM East Coast USA Time
Abstract Session 4
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 05: Assessing the Effect of Previous Antibiotic Usage on Bispecific Monoclonal Antibody Therapy in Multiple Myeloma Patients
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
Speaker: Roberto Garcia-Vicente, MSc (he/him/his) – Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, Madrid, Spain
Oral Abstract Session
Friday, Sep 27th
10:12 AM – 10:24 AM East Coast USA Time
OA – 11: Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 16: Long-term evaluation of minimal residual disease dynamics in Multiple Myeloma patients achieving complete response after first line treatment
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
Speaker: Ioannis V. Kostopoulos, MSc, PhD (he/him/his) – Flow Cytometry Unit, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece
Oral Abstract Session
Friday, Sep 27th
10:36 AM – 10:48 AM East Coast USA Time
OA – 17: Liquid chromatography mass spectrometry (LC-MS) for identification of exceptional responders in newly diagnosed multiple myeloma (NDMM).
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 18: Association of Cardiac biomarkers and Adverse Events with a Carfilzomib-containing Quadruplet in High-risk Newly Diagnosed Multiple Myeloma Patients: Correlative Program of the GMMG-CONCEPT Trial
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA
Discussant: Noopur Raje, MD – Massachusetts General Hospital Cancer Center
Oral Abstract Session
Friday, Sep 27th
2:28 PM – 2:48 PM East Coast USA Time
OA – 27: Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
Location: Plenary Hall, Pavilion 3
Speaker: Kylee Maclachlan, MBChB, PhD – Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA
OA – 42: Single-cell RNA-sequencing of 6 million tumor and immune cells in patients with plasma cell premalignancy unveils co-regulation of disease progression by tumor biology and immune dysregulation
OA – 45: Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study
Location: Plenary Hall, Pavilion 3
Speaker: Ashraf Z. Badros, MD – The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA
Oral Abstract Session
Friday, Sep 27th
3:36 PM – 3:40 PM East Coast USA Time
Introducing Abstract
Location: Plenary Hall, Pavilion 3
Discussant: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
Oral Abstract Session
Friday, Sep 27th
3:40 PM – 4:00 PM East Coast USA Time
OA – 54: Efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study.
Location: Plenary Hall, Pavilion 3
Speaker: Aurore Perrot, MD, PhD – CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France
Co-Chair: Nicola Giuliani, MD, PhD – Department of Medicine and Surgery, University of Parma, Parma, Italy
Oral Abstract Session
Friday, Sep 27th
5:30 PM – 5:42 PM East Coast USA Time
OA – 02: Multiplex CRISPR/Cas9 genome editing of cord blood-derived CAR NK cells to improve their persistence and antitumoral potential against Multiple Myeloma
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
OA – 65: Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update
OA – 07: A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
OA – 12: Interim phase 2 study results of durcabtagene autoleucel (PHE885), a T-Charge™ manufactured BCMA-directed CAR-T cell therapy in patients (pts) with r/r multiple myeloma (RRMM)
OA – 14: PROSPECTIVE FUNCTIONAL BONE DISEASE EVALUATION OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH COMBINED USE OF (18)F-FDG-PET/CT AND WHOLE-BODY DIFFUSION WEIGHTED MAGNETIC RESONANCE
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
Speaker: Marco Talarico, MD – Università di Bologna - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli"
Oral Abstract Session
Friday, Sep 27th
6:18 PM – 6:30 PM East Coast USA Time
OA – 30: Phase 1 Study Of Anitocabtagene Autoleucel For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients
Location: Plenary Hall, Pavilion 3
Speaker: Binod Dhakal, MD, MS – Medical College of Wisconsin, Milwaukee, WI, USA
Oral Abstract Session
Friday, Sep 27th
6:18 PM – 6:30 PM East Coast USA Time
OA – 41: Evaluation of the IMWG 2/20/20 IMWG SMM risk stratification model in a cohort of patients evaluated with modern imaging
Location: Rio de Janeiro Ballroom, Lagune Barra Hotel
Speaker: Panagiotis Malandrakis, MD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
OA – 13: Belantamab mafodotin, pomalidomide, and dexamethasone vs pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma: patient-reported outcomes from DREAMM-8
OA – 31:TRIM28 functions as a key protein homeostasis regulator and mediates proteasome inhibitor resistance in MM
Location: 101 A1-A2, Convention Center
Speaker: Teng Fang, PhD student – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Oral Abstract Session
Saturday, Sep 28th
10:12 AM – 10:24 AM East Coast USA Time
OA – 15: Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions
Location: Plenary Hall, Pavilion 3
Speaker: Neha Korde, MD – Memorial Sloan Kettering Cancer Center
Oral Abstract Session
Saturday, Sep 28th
10:12 AM – 10:24 AM East Coast USA Time
OA – 32: p300 catalytic inhibition selectively disrupts IRF4 oncogenic programs impacting multiple myeloma cell growth and survival
OA – 35: Discovery of a novel class MMSET inhibitor with specificity for t(4;14)-positive multiple myeloma
Location: 101 A1-A2, Convention Center
Speaker: Sae Matsuoka, MD (she/her/hers) – Division of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan
Oral Abstract Session
Saturday, Sep 28th
10:24 AM – 10:36 AM East Coast USA Time
OA – 43: Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma
OA – 09: Mezigdomide enhances activity of BCMA-targeted cellular and T-cell engager therapies and mitigates immune toxicity in preclinical models of multiple myeloma
OA – 29: Mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial
OA – 24: A novel mouse model engineered with human immune system is a translationally-important model for studies related to immune-microenvironment and immunotherapies in multiple myeloma
Location: 101 A1-A2, Convention Center
Speaker: Phaik Ju Teoh, PhD – Cancer Science Institute of Singapore, National University of Singapore
Oral Abstract Session
Saturday, Sep 28th
11:27 AM – 11:39 AM East Coast USA Time
OA – 57: Results of a phase 1 clinical trial of belantamab mafadotin (BelMaf) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma (MM) after one prior line of therapy (LOT)
OA – 58: Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
Location: Plenary Hall, Pavilion 3
Speaker: Abel Costa, MD – D'Or Institute for Research and Education
Oral Abstract Session
Saturday, Sep 28th
11:39 AM – 11:51 AM East Coast USA Time
OA – 66: Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA
Location: 101 A1-A2, Convention Center
Speaker: David Fandrei, MSc – University Leipzig Medical Center, Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, Leipzig, Germany
Oral Abstract Session
Saturday, Sep 28th
11:51 AM – 12:03 PM East Coast USA Time
OA – 33: LILRB4 is a promising dual target for tumor cells and immunosuppressive myeloid cells in multiple myeloma
OA – 61: All oral triplet Iberdomide Ixazomib and Dexamethasone in elderly patients with multiple myeloma patients at first relapse : results of the IFM phase 2 study I2D
OA – 62: Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin, pomalidomide, dexamethasone vs pomalidomide plus bortezomib, dexamethasone (PVd) in relapsed/refractory multiple myeloma
Location: Plenary Hall, Pavilion 3
Speaker: Suzanne Trudel, MD – Princess Margaret Cancer Centre, Toronto, ON, Canada
